Kanat O, O’Neil B, Shahda S. Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 2015; 7(12): 401-410 [PMID: 26690491 DOI: 10.4251/wjgo.v7.i12.401]
Corresponding Author of This Article
Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Uludag University faculty of Medicine, McIntyre Medical Building, 3655 Sir William Osler Montreal, Quebec H3G1Y6, 16059 Bursa, Turkey. ozkanat@uludag.edu.tr
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Dec 15, 2015; 7(12): 401-410 Published online Dec 15, 2015. doi: 10.4251/wjgo.v7.i12.401
Targeted therapy for advanced gastric cancer: A review of current status and future prospects
Ozkan Kanat, Bert O’Neil, Safi Shahda
Ozkan Kanat, Department of Medical Oncology, Uludag University faculty of Medicine, 16059 Bursa, Turkey
Bert O’Neil, Safi Shahda, Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202, United States
Author contributions: All authors contributed equally to writing this review.
Conflict-of-interest statement: Authors declare no conflict of interest for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ozkan Kanat, MD, PhD, Professor, Department of Medical Oncology, Uludag University faculty of Medicine, McIntyre Medical Building, 3655 Sir William Osler Montreal, Quebec H3G1Y6, 16059 Bursa, Turkey. ozkanat@uludag.edu.tr
Telephone: +90-22-42951321
Received: May 21, 2015 Peer-review started: May 22, 2015 First decision: July 1, 2015 Revised: September 18, 2015 Accepted: October 23, 2015 Article in press: October 27, 2015 Published online: December 15, 2015 Processing time: 208 Days and 0.5 Hours
Abstract
In the West in particular, the vast majority of gastric cancer (GC) patients present with advanced-stage disease. Although combination chemotherapy is still the most important component of treatment for these patients, it confers a modest survival advantage. Recently, increased knowledge of the key molecular signaling pathways involved in gastric carcinogenesis has led to the discovery of specific molecular-targeted therapeutic agents. Some of these agents such as trastuzumab and ramucirumab have changed the treatment paradigm for this disease. In this paper, we will summarize the current clinical status of targeted drug therapy in the management of GC.
Core tip: Systemic chemotherapy confers a modest survival advantage in patients with advanced gastric cancer. The new therapeutic agents that target various inter- and intracellular signaling transduction pathways offer the promise of improved clinical outcomes in selected patients. The success of some of these agents has changed the treatment paradigm for advanced gastric cancer. We herein discuss the current and potential future roles of targeted therapy in the management of this malignancy.
